NASDAQ:CDNA - CareDx Stock Price, Price Target & More

CareDx trades on the NASDAQ under the ticker symbol "CDNA."

CareDx (NASDAQ:CDNA) posted its earnings results on Thursday, March, 22nd. The company reported ($0.09) earnings per share for the quarter, topping analysts' consensus estimates of ($0.15) by $0.06. The firm had revenue of $12.50 million for the quarter, compared to the consensus estimate of $12.09 million. CareDx had a negative net margin of 114.79% and a negative return on equity of 349.65%. View CareDx's Earnings History.

4 brokers have issued twelve-month price objectives for CareDx's stock. Their forecasts range from $6.50 to $12.00. On average, they expect CareDx's stock price to reach $8.8750 in the next twelve months. View Analyst Ratings for CareDx.

CareDx saw a decline in short interest in March. As of March 29th, there was short interest totalling 1,164,799 shares, a decline of 78.4% from the March 15th total of 5,387,444 shares. Based on an average trading volume of 889,989 shares, the days-to-cover ratio is presently 1.3 days. Currently, 6.3% of the shares of the stock are sold short.

Some companies that are related to CareDx include ChemoCentryx (CCXI), Vectura Group (VEC), StemlineTherapeutics (STML), Akebia Therapeutics (AKBA), Insys Therapeutics (INSY), American Renal Associates (ARA), SurModics (SRDX), Progenics Pharmaceuticals (PGNX), Achillion Pharmaceuticals (ACHN), ObsEva (OBSV), Zealand Pharma A/S (ZLDPF), Medical Facilities (DR), BioCryst Pharmaceuticals (BCRX), Innate Pharma (IPHYF), Community Health Systems (CYH), MediciNova (MNOV), Zealand Pharma (ZEAL) and Isotechnika Pharma (AUPH).

Media coverage about CDNA stock has been trending somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. CareDx earned a news impact score of 0.09 on Accern's scale. They also gave press coverage about the company an impact score of 46.32 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

CareDx's stock is owned by a number of of retail and institutional investors. Top institutional investors include PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE (3.90%). Company insiders that own CareDx stock include James P Yee, Michael Brian Bell, Mitchell J Nelles, Neil Gagnon and Peter Maag. View Institutional Ownership Trends for CareDx.

Shares of CDNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CDNA stock can currently be purchased for approximately $9.29.

CareDx has a market capitalization of $267.49 million and generates $48.32 million in revenue each year. The company earns $-55,460,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis. CareDx employs 179 workers across the globe.

CareDx's mailing address is 3260 BAYSHORE BOULEVARD, BRISBANE CA, 94005. The company can be reached via phone at 415-287-2300 or via email at [email protected]